(Q28280465)
Statements
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (English)
0 references
Kim A Papp
1 reference
17 May 2008
0 references
371
0 references
9625
0 references
1675-84
0 references